cisplatin,toripalimab,avelumab,ruxolitinib,sacituzumab govitecan,sacituzumab govitecan,disitamab vedotin,pembrolizumab,enfortumab vedotin,cabozantinib,trastuzumab deruxtecan,nivolumab
merck,astellas,daiichi sankyo,astrazeneca,bms,novartis,pfizer,rongchang pharma,gilead sciences,junshi biosciences,seagen,incyte,coherus
['toripalimab', 'trastuzumab deruxtecan', 'vedo', 'avelumab', 'nivolumab', 'disitamab', 'pembro', ' vedo', 'cisplatin', 'sacituzumab', 'tdxd', 'rc48', 'urothelial', 'cabozantinib', 'urothelial carcinoma', 'rux,(-crux),(-trux)', 'enfortumab', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'sacitu, govi', 'nivo', 'bladder', ' uc,(-ucsd),(-ucsf),']
what is the right sequence met. urothelial carcinoma"? great overview -sequence does matter in terms of efficacy and toxicity
jh. hoffman-censits #gu23 #medtwitter #bladdercancer 
On the road!
Pursuing to improve global health through sharing knowledge, cancer prevention, and care.  
Medical oncologist @AnkaraUni